Every breast cancer patient
deserves a personalized
treatment plan

BluePrint: a test to predict likely tumor behavior

BluePrint,* a molecular subtyping test, analyzes the activity of 80 genes to enable stratification of the tumor into one of the three following subtypes: Luminal-type, HER2-type and Basal-type. By combining MammaPrint and BluePrint, patients can be stratified into the following four subgroups: Luminal-type/MammaPrint Low Risk (Luminal A§); Luminal-type/MammaPrint High Risk (Luminal B||); HER2-type and Basal-type patients.1

Each breast cancer subtype is markedly different in its degree of aggressiveness, long-term outcome, and response to chemotherapy. With subtype information, provided by BluePrint in combination with MammaPrint, physicians are better informed to make decisions about a patient’s specific options, thereby personalizing her treatment.

Impacted by COVID-19? You may be eligible for a deferred payment plan.
[email protected]

In a 2013 study2 adding BluePrint molecular subtyping to MammaPrint helped to better predict a patient’s prognosis and aid in the choice of therapy, versus traditional methods like IHC and FISH.

21% of patients were reclassified as MammaPrint Low Risk, BluePrint Luminal-Type A and showed little, if any, benefit from chemotherapy.2

Read the study

It is important to properly select the right patients for the right neoadjuvant chemotherapy. Functional molecular subtyping with the 80 gene assay, BluePrint, further drives precision oncology, providing valuable insight into a patient’s tumor biology to better inform these treatment decisions.

— Dr. Pat Whitworth, MD

Where to next?

How to order
Contact Us
Published studies
Ongoing studies

*BluePrint is a laboratory-developed test that was developed, validated and is performed exclusively by Agendia. The test is intended for clinical purposes. The test has not been cleared by the U.S. Food and Drug Administration (FDA) but has been CE-marked for use in Europe. The laboratory is regulated under the Clinical Laboratory Improvement Amendments (CLIA) to ensure the quality and validity of the tests. Our laboratories are CAP-accredited and certified under CLIA to perform high complexity clinical laboratory testing.

The molecular subtype HER2 type is not the same as HER2-positive and is not used to guide treatment. Although most HER2 type tumors are HER2-positive (and named for this reason), about 30 percent are HER2-negative. HER2 type tumors tend to be: ER-negative, PR-negative, lymph node-positive and poorer tumor grade.

Basal-type is a molecular subtype of breast cancer that contains a certain cluster of genes expressed by cells in the outer layer (basal) of the adult mammary gland. Basal cancers generally test negative for ER, PgR and HER2, and are considered particularly aggressive.

§Luminal A is a molecular subtype of breast cancer that is ER/PgR-positive but negative for HER2. This is the most common subtype.

||Luminal B is a molecular subtype of breast cancer that tends to be ER-positive, PgR-negative, HER2-negative, and exhibits high levels of proliferative markers.


1. Glück S, de Snoo F, Peeters J, Stork-Sloots L, Somlo G. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy. Breast Cancer Res Treat. 2013; 139(3):759-67

2. Krijgsman O, Roepman P, Zwart W, et al. A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Res Treat. 2012; 133:37-47